There is no single best prescription medicine for arthritis pain. The right choice depends on which type of arthritis you have, how severe your symptoms are, and how your body responds to treatment. For osteoarthritis, prescription-strength anti-inflammatory drugs are the first line. For rheumatoid arthritis, disease-modifying drugs that slow joint damage take priority. Here’s how each category performs and what to realistically expect from them.
Prescription NSAIDs for Osteoarthritis
The American College of Rheumatology and the Arthritis Foundation strongly recommend oral NSAIDs as a core treatment for osteoarthritis of the knee, hip, and hand. These drugs reduce both pain and inflammation, and they remain the most widely prescribed option for moderate to severe osteoarthritis symptoms.
Not all prescription NSAIDs work equally well. A large network meta-analysis comparing multiple NSAIDs for knee osteoarthritis ranked them by their probability of being the most effective. For overall symptom relief, diclofenac came out on top with an 80.6% probability of being the best option, compared to 45.5% for naproxen and 41.9% for celecoxib. For pure pain reduction, etoricoxib ranked highest at 84.4%, followed by naproxen at 79.6% and diclofenac at 71.3%. Celecoxib, despite being one of the most commonly prescribed options, ranked lower for pain at 45.6%.
The picture shifts when you look at physical function. Naproxen ranked as the most effective NSAID for improving daily function in osteoarthritis patients, with a 72.9% probability of being best, followed by diclofenac at 63.2%. For stiffness specifically, diclofenac was the only NSAID that showed a statistically significant improvement over placebo.
Guidelines recommend using the lowest effective dose for the shortest time possible. This matters because long-term NSAID use carries real risks to the stomach, kidneys, and cardiovascular system.
Topical vs. Oral NSAIDs
Before reaching for an oral NSAID, the ACR guidelines recommend trying topical versions first, particularly for knee and hand osteoarthritis. Prescription-strength topical diclofenac gel delivers the drug directly to the joint with far less systemic exposure, which means fewer stomach and cardiovascular side effects.
The tradeoff is effectiveness. In a randomized trial comparing topical diclofenac to oral ibuprofen for musculoskeletal pain, the oral version produced noticeably better pain improvement: a 10.1-point reduction on a pain scale versus 6.4 points for the topical gel. Adding topical diclofenac on top of oral ibuprofen didn’t provide any additional benefit. Topical NSAIDs work best for joints close to the skin surface, like knees and hands, and less well for deeper joints like the hip.
Corticosteroid Injections
Steroid injections directly into an arthritic joint provide fast, targeted relief, but the effect is short-lived. Systematic reviews show the average pain reduction lasts only 2 to 4 weeks, with clear efficacy at the 4-week mark (about 18 points on a 100-point pain scale) that fades significantly by 3 months and disappears entirely by one year. Because the relief is temporary, injections are typically limited to about 4 per year in any given joint. They’re most useful for flare-ups or when you need short-term relief for a specific event, not as a long-term management strategy.
Methotrexate for Rheumatoid Arthritis
If you have rheumatoid arthritis or another inflammatory arthritis, the goal shifts from managing pain to controlling the immune system’s attack on your joints. Pain relief follows from reducing that underlying inflammation, not from painkillers alone.
Methotrexate is the first-line treatment recommended by every major rheumatology guideline worldwide, including the ACR, the European League Against Rheumatism, and the Japan College of Rheumatology. It works by dampening the overactive immune response that drives joint destruction. Most clinical studies on newer arthritis drugs use methotrexate as the baseline comparison because it remains the standard against which everything else is measured.
Methotrexate carries a 3% annual risk of serious infection, meaning 3 out of every 100 people taking it for a year will experience one. It also requires regular blood monitoring to check liver function and blood cell counts. Despite these risks, it has decades of safety data behind it and is generally well tolerated. It takes several weeks to reach full effectiveness, so you may need bridging pain relief with NSAIDs or short-term corticosteroids while waiting for it to kick in.
Biologic Drugs for Resistant Cases
When methotrexate alone isn’t enough, biologic drugs are the next step. These are typically given by injection or infusion and target specific parts of the immune system. The most established class blocks a protein called TNF-alpha, which drives inflammation in rheumatoid arthritis.
For patients who haven’t responded to one previous biologic, switching to a new one produces meaningful improvement (at least 20% better) in about 70% of cases. That success rate drops with each additional switch: roughly 53% after two prior biologics and 41% after three. The chance of achieving major improvement (70% or better symptoms) sits around 19% with a first switch and drops to about 12% with subsequent ones.
Adding a biologic to methotrexate does increase the risk of serious infection from 3% to about 5% per year. Your rheumatologist will weigh this against the benefit of better disease control and less joint damage over time.
When Pain Doesn’t Match Inflammation
Some people with arthritis have pain that seems out of proportion to what’s visible on imaging or blood tests. This happens because chronic arthritis can rewire how your nervous system processes pain, a phenomenon called central sensitization. The brain and spinal cord become amplifiers, making normal sensations feel painful.
For this type of pain, standard anti-inflammatories won’t fully help because the problem isn’t just in the joint. Medications that act on the central nervous system can fill this gap. In a randomized, placebo-controlled trial of people with hand osteoarthritis, both pregabalin and duloxetine significantly reduced pain compared to placebo. Pregabalin showed the stronger and more sustained effect, while duloxetine reached statistical significance after 13 weeks of treatment. These drugs work through different mechanisms: duloxetine boosts serotonin and noradrenaline (brain chemicals involved in pain suppression), while pregabalin calms overexcited nerve signaling.
These aren’t replacements for NSAIDs or disease-modifying drugs. They work best as add-on treatments for people whose pain persists despite standard therapy, particularly when the pain has features like widespread tenderness, sensitivity to touch, or pain that doesn’t correlate with the degree of joint damage visible on X-rays.
Matching the Medicine to Your Arthritis
The “best” prescription depends entirely on your situation. For osteoarthritis with moderate to severe pain, diclofenac or naproxen offer the strongest evidence for overall symptom control. If stomach or heart risks concern you, starting with topical diclofenac makes sense for accessible joints. For rheumatoid arthritis, methotrexate is the clear first choice, with biologics reserved for when it falls short. And if your pain has a sensitization component, adding a centrally acting medication like pregabalin or duloxetine can address what anti-inflammatories miss.
Most people with arthritis end up using more than one medication at different stages. What works in year one may need adjustment in year five as your disease changes, your body adapts, or new side effects emerge. The goal isn’t finding one perfect drug but building a regimen that controls your symptoms while keeping risks manageable.